Shares of NPS Pharmaceuticals Inc. (NASDAQ:NPSP) have more than tripled in value since hitting a low of $2.74 in June 2009. Much of the upward push came from positive news flow for the company's short bowel syndrome candidate Gattex teduglutide. The analog of glucagon-like peptide-2 (GLP-2) received a favorable FDA panel vote last week. Europe approved the drug as Revestive in September. NPS focused on Gattex soon after receiving a 2006 FDA approvable letter for osteoporosis candidate Preos recombinant human parathyroid hormone 1-84. The agency requested an additional Phase III trial, in part to allay concerns about the risk of hypercalcemia associated with Preos. Last year, NPS said the product, now